Posted by Michael Wonder on 22 Feb 2019
ICER’s assessment finds Spinraza and Zolgensma provide substantial health benefits for people with spinal muscular atrophy
22 February 2019 - Current pricing of Spinraza would require a substantial discount to meet traditional cost-effectiveness ranges; Zolgensma’s value-based price range is between $310,000-$900,000 using standard methodology but as high as $1.5 million using alternative measures of health gain.
The Institute for Clinical and Economic Review today released an Evidence Report assessing the comparative clinical effectiveness and value of nusinersen (Spinraza, Biogen) and onasemnogene abeparvovec (Zolgensma, Novartis/AveXis) for the treatment of spinal muscular atrophy (SMA). Spinraza was approved in 2016 for treatment of SMA in both children and adults.
Zolgensma is a gene therapy that has been studied in infants with Type I SMA, and an FDA decision is expected in the first half of 2019.
